Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrated pharmacokinetics of anti-TNF agents in serum, tissue, and feces in moderate to severe colitis
NL-OMON47648Active, not recruiting
- Sponsor
- Maag-, darm-, leverziekten
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of infliximab, adalimumab and golimumab in autoimmune colitis, Crohn's colitis and inflammatory bowel disease (IBD) (3 cohorts), sponsored by Maag-, darm-, leverziekten. Started Feb 2016; status: active, not recruiting.
02
Drugs
03
Conditions
autoimmune colitisCrohn's colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON47648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47648.